This heterogeneity of response of various prostate cancer cells to alterations in KLK3 expression may explain why a lower level of CDH1 in CTCs was only observed in one of four models, despite the consistent decrease in KLK3 across all models, in the present study. This evidence concerns the gene CDH1 and prostate cancer.